What is FDA’s safety and performance-based pathway? Why is it an alternative to substantial equivalence for 510(k) submissions? Why should medical device manufacturers opt for this approach? How is it beneficial to access the US market? For comprehensive insights, read through Freyr’s thought leadership published on Med Device Online, authored by Jeffrey S. Eberhard.